ConductScience.org, home

Paper · 41869723

DAB2 in LGMD R2: a molecular link between disease progression and lipid dysregulation.

Bruge C and 16 others. JCI Insight, 2026. Cited by 1 paper, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. DAB2 in LGMD R2: a molecular link between disease progression and lipid dysregulation. Papers, record 41869723. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41869723

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
DAB2 in LGMD R2: a molecular link between disease progression and lipid dysregulation.
PubMed
Journal
JCI Insight
PubMed
Year
2026
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-09-07
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bruge CCeline
2Bourg NNathalie
3Pellier EEmilie
4Miagoux QQuentin
5Benabides MManon
6Grossi NNoella
7Hayat HHassan
8Jarrige MMargot
9Polveche HHelene
10Agostini VValeria

1 to 10 of 17Source PubMed

See all 17 authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Lipid MetabolismMajor topic
Muscular Dystrophies, Limb-GirdleMajor topic
Adaptor Proteins, Vesicular TransportMajor topic
Adaptor Proteins, Signal TransducingMajor topic
Animals
Humans
Mice
Disease Progression
Dysferlin
Muscle Fibers, Skeletal
Induced Pluripotent Stem Cells
Male
Muscle, Skeletal
Female
Disease Models, Animal
Apoptosis Regulatory Proteins

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References80

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125,313,409Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy.J Cell Biol2014https://conductscience.org/library/papers/25313409PubMed
226,290,039Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells.Sci Rep2015https://conductscience.org/library/papers/26290039PubMed
328,707,952Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy.Hum Gene Ther2018https://conductscience.org/library/papers/28707952PubMed
431,105,274Estimating prevalence for limb-girdle muscular dystrophy based on public sequencing databases.Genet Med2019https://conductscience.org/library/papers/31105274PubMed
529,034,878Generation of an induced pluripotent stem cell line (CSCRMi001-A) from a patient with a new type of limb-girdle muscular dystrophy (LGMD) due to a missense mutation in POGLUT1 (Rumi).Stem Cell Res2017https://conductscience.org/library/papers/29034878PubMed
620,082,313Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle.Muscle Nerve2010https://conductscience.org/library/papers/20082313PubMed
727,333,044Human Pluripotent Stem Cell-derived Cortical Neurons for High Throughput Medication Screening in Autism: A Proof of Concept Study in SHANK3 Haploinsufficiency Syndrome.EBioMedicine2016https://conductscience.org/library/papers/27333044PubMed
834,831,431Therapeutic Benefit of Galectin-1: Beyond Membrane Repair, a Multifaceted Approach to LGMD2B.Cells2021https://conductscience.org/library/papers/34831431PubMed
925,260,700HTSeq--a Python framework to work with high-throughput sequencing data.Bioinformatics2015https://conductscience.org/library/papers/25260700PubMed
1030,439,648Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy.Mol Ther Nucleic Acids2018https://conductscience.org/library/papers/30439648PubMed

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
42,406,575Excess muscle plasma membrane leak disrupts ECM content and shifts macrophage-mediated muscle repair.JCI Insight2026https://conductscience.org/library/papers/42406575

Source PubMed

Genes24

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41869723

GET https://conductscience.org/api/papers/v1/41869723/references?page=2